Trials / Completed
CompletedNCT02518048
A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris
A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LEO 90100 Aerosol Foam Compared to Betesil® Medicated Plaster in the Treatment of Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the anti-psoriatic effect of LEO 90100 aerosol foam compared with Betesil® medicated plaster
Detailed description
The products will be applied on 6 test sites (each product on 3 test sites) once daily 6 days a week (except Sundays) for 4 weeks. The application sites for each product will be determined according to random assignment. Depending on the size of the psoriasis plaques, 2 or 4 test sites will be located within the same plaque; the treatment assignment will be done pair-wise.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 90100 Aerosol foam | |
| DRUG | Betesil® 2.25 mg |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2015-08-07
- Last updated
- 2025-03-10
- Results posted
- 2017-04-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02518048. Inclusion in this directory is not an endorsement.